Meitheal Pharmaceuticals

What Meitheal Pharmaceuticals does

Meitheal Pharmaceuticals is a privately held, fully integrated biopharmaceutical company founded in 2017 and headquartered in Chicago, Illinois. The company develops and commercializes a diversified portfolio of FDA-approved generic injectable medications, branded specialty pharmaceuticals, biosimilars and biologics, and fertility products, marketed under the Meitheal Pharmaceuticals and Meitheal Fertility brands. As of July 2025, the portfolio includes over 70 on-market products spanning anti-infectives, oncolytics, intensive care, fertility, and immunology, with 22 additional products under FDA review and 29 in active R&D. The company is a wholly-owned U.S. commercial subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), a publicly listed Shanghai Stock Exchange company with a market capitalization exceeding US $3.0 billion, which provides three FDA-approved manufacturing sites in China, over $300 million in cumulative capital and R&D investment, and a pipeline of biosimilars, insulin analogs, and specialty products commercialized through Meitheal.

The core technology and competitive moat derive from vertical integration via NKF—API manufacturing through finished dosage form at a capacity exceeding 200 million units annually—combined with exclusive U.S. commercialization rights to differentiated assets including YUSIMRY (Humira biosimilar), XENLETA and CONTEPO (antibiotics), XTMAB-16 (Orphan Drug-designated anti-TNF for pulmonary sarcoidosis), and three insulin biosimilars. Meitheal generates revenue through direct sales of generic injectables to hospitals and healthcare systems, licensing royalties and milestone payments on biosimilars and branded specialty products (Xentria, Coherus, Nabriva, Tonghua Dongbao deals), and working-capital-backed growth under a J.P. Morgan senior secured revolving credit facility of $35 million (expandable to $80 million). Distribution is conducted through all three major U.S. pharmaceutical wholesalers—Cardinal, Cencora, McKesson—and Morris-Dickson, with an enterprise field sales force and medical science liaison team supporting specialty products. Customer concentration is moderate, anchored in acute care hospitals, health systems, fertility clinics, and oncology centers, with growth validated by Meitheal's ranking as the #2 company on Crain's Chicago Fast 50 in 2024.

Name

Meitheal Pharmaceuticals

Legal name

Meitheal Pharmaceuticals, Inc.

Website

https://meithealpharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Meitheal Pharmaceuticals is a Chicago-based, privately held biopharmaceutical company that develops and commercializes over 70 FDA-approved generic injectables, branded specialty drugs, biosimilars, and fertility products, serving U.S. hospitals, health systems, and fertility clinics through major wholesale distributors.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Sterile Injectable Generics (HLAIABAC)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic Hospital & Institutional Products (HLAIABAL), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Generic injectables
• Branded pharmaceuticals
• Biosimilars manufacturing
• Fertility therapeutics
• Hospital pharmaceuticals

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Generic Injectable Product Sales: Meitheal generates revenue primarily through the sale of FDA-approved generic injectable medications across therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. The company markets over 70 U.S. FDA-approved products through direct sales and distribution partnerships.
2. Branded Product Licensing and Royalties: Revenue is generated through exclusive licensing agreements for branded products like YUSIMRY (biosimilar of Humira) and XTMAB-16. The company receives royalties on net sales from licensed products and milestone payments upon regulatory achievements.
3. Working Capital Financing: Meitheal secured a $35 million senior secured revolving credit agreement with J.P. Morgan (expandable to $80 million) maturing August 2026 for working capital and strategic growth initiatives.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Meitheal Pharmaceuticals is a fully integrated biopharmaceutical company that develops, manufactures (via parent NKF), and commercializes a diversified portfolio of over 70 FDA-approved generic injectable medications, branded specialty products, biologics/biosimilars, and fertility therapies across anti-infective, oncology, intensive care, and fertility therapeutic areas in the United States. The company markets products directly to hospitals, healthcare systems, fertility clinics, and major wholesale distributors through an enterprise field sales organization and authorized distribution network.

Product overview

Meitheal Pharmaceuticals is a fully integrated biopharmaceutical company that develops and commercializes a diversified portfolio of generic injectables, branded products, biologics/biosimilars, and fertility products. The core offerings include over 70 FDA-approved generic injectable medications across anti-infectives, oncolytics, intensive care, and fertility therapeutic areas. The branded portfolio features XENLETA (lefamulin) antibiotic and CONTEPO (fosfomycin for injection), while the biologics division encompasses biosimilars including YUSIMRY (Humira biosimilar), insulin biosimilars (aspart, lispro, glargine), and XTMAB-16 for pulmonary sarcoidosis. Meitheal Fertility provides fertility therapies including Ganirelix pen and FSH biosimilar. Recent expansion includes liraglutide injection (first diabetes medication and injector pen product) and paclitaxel (oncology). The company operates through global strategic partnerships with parent company Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) and other partners.

Differentiator

Problem solved

Functional benefit

Brands

• Meitheal Fertility: Bringing affordable therapies to families on their IVF journey. Introduced multi-dose Ganirelix pen to simplify medication administration.

Products and services

• Generic Injectable Pharmaceuticals Portfolio
• XENLETA (lefamulin)
• CONTEPO (fosfomycin for injection)
• YUSIMRY (adalimumab-aqvh)
• XTMAB-16
• Liraglutide Injection
• Paclitaxel Protein-Bound Particles for Injectable Suspension
• Mitoxantrone Injection, USP
• Daunorubicin Hydrochloride Injection
• IDArubicin Hydrochloride Injection, USP
• Adenosine Injection, USP
• Norepinephrine Bitartrate Injection, USP
• Fluorouracil Injection, USP 5 g
• Cyanocobalamin Injection, USP (New Strengths)
• Methylene Blue Injection, USP
• Alprostadil Injection, USP
• Doxycycline for Injection, USP
• Propofol Injectable Emulsion, USP
• Vecuronium Bromide for Injection
• Dalbavancin for Injection
• Octreotide Acetate Injection
• Palonosetron Hydrochloride Injection
• Meitheal Fertility (Ganirelix Multi-Dose Pen and FSH Biosimilar)
• Insulin Biosimilars Portfolio (Aspart, Lispro, Glargine)

Quantifiable outcome

• Over 70 FDA-approved products on market as of July 2025
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF)flagshipStrategic or Co-development PartnerNKF is Meitheal's parent company and primary strategic partner. Founded in 1986, NKF is a China-based fully integrated API and FDF manufacturer with three U.S. FDA approved manufacturing sites. Publicly listed on Shanghai Stock Exchange with market cap over U.S. $3.0 billion. Provides manufacturing, R&D investment (over $300 million), and pipeline development support.
• Tonghua Dongbao Pharmaceutical Co., Ltd. (THDB)coreStrategic or Co-development PartnerExclusive licensing agreement to commercialize three insulin biosimilars (insulin aspart, insulin lispro, and insulin glargine) in the U.S. THDB and NKF jointly responsible for development and supply. FDA approval estimated around 2026. Founded in 1985, first Chinese company to develop and commercialize insulins.
• Xentria Inc.coreStrategic or Co-development PartnerExclusive multi-year licensing agreement to commercialize XTMAB-16 (anti-TNFalpha antibody) for pulmonary sarcoidosis in North America. Xentria receives $45 million upfront, $35 million on regulatory submission/approval, and potential royalties exceeding $600 million over term. IP transfers to HKF upon achievement of $600 million in royalties.
• Coherus BioSciences, Inc.coreOEM/ Whitelabel/ Licensing PartnerAcquired worldwide rights to YUSIMRY (biosimilar of Humira) through asset purchase from Coherus. HKF paid $40 million upfront cash payment. Meitheal gained exclusive U.S. commercial rights. YUSIMRY approved for nine indications with additional formulations expected in 2025.
• Nabriva TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerAcquired North America rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics. Acquired all IP rights, technology, and know-how. Nabriva received payment at closing plus royalty on net U.S. sales. NDA under FDA review for cUTI treatment.
• Hong Kong King-Friend Industry Co., Ltd. (HKF)flagshipStrategic or Co-development PartnerWholly-owned subsidiary of NKF, founded in 2010. HKF has acquired worldwide rights to multiple products including YUSIMRY and grants exclusive U.S. commercialization rights to Meitheal. Invested over $300 million in capital and R&D supporting Meitheal's product portfolio.
• Boan BiotechminorStrategic or Co-development PartnerPartner for denosumab biosimilar development, listed in Meitheal's biologics pipeline under Immunology & Inflammation therapeutic area.
• Integrated Commercialization Solutions, Inc. (ICS)minorChannel Partner/ Reseller/ DistributorApproved return goods agent for Meitheal handling product returns from customers. Located at 6450 LaSalle Dr., Lockbourne, OH 43137. Provides customer service phone support at 844-824-8426.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Sagent Pharmaceuticals: Specialty generic injectable company with a U.S. hospital-channel focus. Direct competitor in the same product categories Meitheal targets, including anti-infectives and critical care.
• Hikma Pharmaceuticals: Generic injectable manufacturer with a broad U.S. hospital-focused portfolio across anti-infectives, oncology, and critical care. Direct competitor to Meitheal in sterile injectable generics distributed through major wholesalers.
• Amphastar Pharmaceuticals: U.S.-based specialty injectable manufacturer with a portfolio spanning emergency, anesthesia, and oncology injectables. Comparable in size and channel mix to Meitheal's generic injectable franchise.
• Fresenius Kabi: Global manufacturer of generic injectable pharmaceuticals with extensive U.S. hospital-channel presence in anti-infectives, analgesics, and critical care. Direct overlap with Meitheal's hospital injectable portfolio.

Broad incumbents

• Hospira (Pfizer): Largest U.S. generic injectable franchise, now part of Pfizer. Competes directly with Meitheal in hospital injectables while also offering broader pharmaceutical capabilities as a large incumbent.
• Aurobindo Pharma: Vertically integrated Indian generic manufacturer with significant U.S. injectable and oral solid presence. Competes with Meitheal in hospital injectables with broader portfolio scale.
• Sun Pharmaceutical Industries: Large global generic manufacturer with a U.S. specialty and injectable business. Comparable to Meitheal in offering complex generics and biosimilars, with much broader scale.
• Lupin Pharmaceuticals: Vertically integrated generics company with a U.S. injectable and complex generics business. Overlaps with Meitheal in hospital injectables and specialty pharmaceuticals.

Emerging players

• Coherus BioSciences: Biosimilar-focused company from which Meitheal (via HKF) acquired YUSIMRY rights. Comparable in biosimilar commercial focus and a relevant prior counterparty for competitive positioning.
• Xentria: Clinical-stage biotech that licensed XTMAB-16 to Meitheal for North America. Relevant comparator as a smaller specialty/biologic counterparty developing in the same anti-TNF space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/meitheal-pharmaceuticals-inc.
• Xx.com/meithealpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meitheal Pharmaceuticals